All News #Library
Rare Diseases
Rallybio`s RLYB116 Inhibits Terminal Complement in Ph1
17 Feb 2026 //
BUSINESSWIRE
Rallybio Completes 1st Cohort Dosing In RLYB116 Ph 1 PK/PD Study
25 Sep 2025 //
BUSINESSWIRE
Rallybio Gets $12.5M Equity Milestone from Recursion for REV102
03 Sep 2025 //
PHARMAWEB
Rallybio Exits Recursion Pact, Changes Direction
08 Jul 2025 //
FIERCE BIOTECH
Rallybio Pivots as Antibody for Rare Bleeding Disorder Flunks Trial
09 Apr 2025 //
BIOSPACE
AbCellera and Rallybio Announce Strategic Alliance to Discover, Rare Diseases
01 Dec 2022 //
BUSINESSWIRE

Market Place
Sourcing Support